Kevin Lobo - Stryker President CEO, Director

SYK Stock  EUR 309.50  1.50  0.49%   

CEO

Mr. Kevin A. Lobo is Chairman of the Board, Chief Executive Officer of the Company. He was named Chairman of the Board in July 2014 and has served as Chief Executive Officer of the Company since 2012. He joined the Company as a Group President in April 2011. Prior thereto, he held leadership roles over eight years with Johnson Johnson, including president of Ethicon EndoSurgery. Mr. Lobo is also a director of ParkerHannifin Corporationrationration, a manufacturer of motion and control technologies and systems since 2018.
Age 58
Tenure 6 years
Phone269 385 2600
Webhttps://www.stryker.com
Lobo global business and leadership experience across multiple industries, including healthcare, enables him to provide valuable insight to the Board regarding the Company operations and the strategic planning initiatives necessary to meet the demands of the changing environment. As the sole member of management on our Board, he provides management business perspectives and the necessary link to the Company daytoday operations.

Stryker Management Efficiency

The company has return on total asset (ROA) of 0.0618 % which means that it generated a profit of $0.0618 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1498 %, meaning that it generated $0.1498 on every $100 dollars invested by stockholders. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 11.86 B in total debt with debt to equity ratio (D/E) of 74.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Stryker has a current ratio of 2.03, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Stryker until it has trouble settling it off, either with new capital or with free cash flow. So, Stryker's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Stryker sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Stryker to invest in growth at high rates of return. When we think about Stryker's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 8 records

CEO Age

Tony HunterNorAm Drilling AS
53
Anders StormSIVERS SEMICONDUCTORS AB
50
Eddy HartensteinNorAm Drilling AS
64
Z ChenOrigin Agritech
49
Luc DesjardinsSuperior Plus Corp
65
John BatterNorAm Drilling AS
52
Peter LiguoriNorAm Drilling AS
53
Nils LarsenNorAm Drilling AS
N/A
Stryker Corporation operates as a medical technology company. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan. STRYKER CORP operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 36000 people. Stryker (SYK) is traded on Frankfurt Exchange in Germany and employs 51,000 people.

Management Performance

Stryker Leadership Team

Elected by the shareholders, the Stryker's board of directors comprises two types of representatives: Stryker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stryker. The board's role is to monitor Stryker's management team and ensure that shareholders' interests are well served. Stryker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stryker's outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew Silvernail, Independent Director
Fink, Vice President Global Human Resources
Sherilyn McCoy, Independent Director
Robert Cohen, CTO Replacement
Ronda Stryker, Independent Director
Curtis Hall, Chief Legal Officer
Spencer Stiles, Group Spine
Andrew Pierce, Group Neurotechnology
William Berry, Principal Accounting Officer, Vice President Corporate Controller
Allan Golston, Independent Director
Katherine Owen, Vice President - Strategy and Investor Relations
Graham Mclean, President Asia-Pacific
Louise Francesconi, Independent Director
Kevin Lobo, President CEO, Director
Jason Beach, VP Relations
Roch Doliveux, Independent Director
David Floyd, Group President - Orthopaedics
William Jellison, CFO, Vice President
Yin Becker, Vice President of Communication and Public Affairs
Timothy Scannell, Group President - MedSurg and Neurotechnology
William Parfet, Non-Executive Independent Chairman of the Board
Robert Fletcher, Vice President Chief Legal Officer
Dean Bergy, Vice President Corporate Secretary
Rajeev Suri, Independent Director
Alan Douville, Chief VP
Glenn Boehnlein, CFO, Vice President
Viju Menon, Group President - Global Quality and Business Operations
Lonny Carpenter, Group President - Global Quality and Operations
Bijoy Sagar, CIO, Vice President
Mary Brainerd, Director
Srikant Datar, Independent Director
Michael Hutchinson, General Counsel
Bronwen Taylor, Vice President - Compliance and Risk Management
Howard Cox, Independent Director
Steven Benscoter, Vice President - Human Resources
Kathryn Fink, Chief Human Resource Officer, Vice President
Scott Bruder, Vice President Chief Medical and Scientific Officer

Stryker Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stryker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Stryker in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Stryker's short interest history, or implied volatility extrapolated from Stryker options trading.

Currently Active Assets on Macroaxis

When determining whether Stryker is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stryker Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stryker Stock. Highlighted below are key reports to facilitate an investment decision about Stryker Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Stryker Stock please use our How to Invest in Stryker guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Complementary Tools for Stryker Stock analysis

When running Stryker's price analysis, check to measure Stryker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stryker is operating at the current time. Most of Stryker's value examination focuses on studying past and present price action to predict the probability of Stryker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stryker's price. Additionally, you may evaluate how the addition of Stryker to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Please note, there is a significant difference between Stryker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Stryker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stryker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.